Evolent Health (EVH) Expected to Announce Quarterly Earnings on Tuesday

Evolent Health (NYSE:EVH) is expected to post its Q4 2025 results after the market closes on Tuesday, February 24th. Analysts expect Evolent Health to post earnings of $0.06 per share and revenue of $468.4810 million for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 5:00 PM ET.

Evolent Health Price Performance

Shares of NYSE EVH opened at $2.79 on Tuesday. The company has a debt-to-equity ratio of 1.25, a quick ratio of 1.33 and a current ratio of 1.33. Evolent Health has a one year low of $2.56 and a one year high of $12.06. The company’s fifty day moving average is $3.69 and its two-hundred day moving average is $6.16. The firm has a market capitalization of $310.81 million, a P/E ratio of -1.76 and a beta of 0.27.

Institutional Investors Weigh In On Evolent Health

Institutional investors and hedge funds have recently modified their holdings of the stock. Brighton Jones LLC acquired a new position in shares of Evolent Health in the 4th quarter valued at about $3,927,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Evolent Health by 2.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 128,527 shares of the technology company’s stock worth $1,217,000 after buying an additional 3,572 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Evolent Health by 162.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,836,402 shares of the technology company’s stock valued at $26,861,000 after buying an additional 1,754,520 shares during the period. Caxton Associates LLP acquired a new stake in shares of Evolent Health during the 1st quarter valued at $252,000. Finally, Strs Ohio purchased a new position in shares of Evolent Health during the 1st quarter valued at $47,000.

Analyst Ratings Changes

Several analysts have recently weighed in on EVH shares. Truist Financial lowered their target price on Evolent Health from $16.00 to $10.00 and set a “buy” rating for the company in a research note on Monday, November 10th. Citigroup dropped their price objective on Evolent Health from $9.50 to $6.00 and set a “buy” rating on the stock in a report on Friday, January 9th. Piper Sandler set a $6.00 price target on shares of Evolent Health in a research report on Tuesday, December 2nd. BTIG Research dropped their price target on shares of Evolent Health from $16.00 to $10.00 and set a “buy” rating for the company in a research note on Monday, February 2nd. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Evolent Health in a report on Monday, December 29th. Thirteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $9.77.

Evolent Health Company Profile

Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company’s core offerings include care management solutions, population health analytics and clinical advisory services.